antibody drug conjugate

FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...

Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...

Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...

SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...

CHENGDU, China, May 12, 2026 Kelun-Biotech announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products...

SAN CARLOS, Calif., April 20, 2026 Synthetic Design Lab announced the first public presentation of its SYNTHBODY™ platform at...

Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...

Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...

North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...

SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...